When it comes to the drug makers, your pipeline is the only thing that matters. How quickly you can refresh and fill gaining blockbusters is what keeps the dividends going. Luckily, for our latest Best Dividend Stocks Model Portfolio pick, its rich pipeline has plenty of potential to keep its dividend going strong. Investors can take advantage of its latest payout by buying the stock before it goes ex-dividend on Tuesday, March 14!
You can check out the Best Dividend Stocks Model Portfolio to explore all the stocks.
Our pick is already pharmaceutical royalty, with a rich cancer drug portfolio. Thanks to sales of several key new oncology drugs, our pick remains awash in cash, and it’s continued to reward investors with buybacks and dividend growth.
However, our pick has smartly used excess cash to continue expanding its portfolio of drugs and pipeline potential. New cardiology medicines are starting to bear fruit, while the firm has continued to conduct M&A of smaller biotech rivals to increase its position in cancer and other disease therapies.
The end result is a top dividend name that continues to feed the machine. Longer term cash flow and dividends are assured thanks to our pick’s smart use of cash and research funding.
